American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis

Geoffrey C. Nguyen, Walter E. Smalley, Santhi Swaroop Vege, Alonso Carrasco-Labra

Research output: Contribution to journalArticle

Abstract

These actionable recommendations for the medical management of microscopic colitis were developed under the framework of the GRADE methodology and were consistent with the Institute of Medicine's Standards for Developing Trustworthy Clinical Practice Guidelines. This guideline is intended to reduce practice variation and promote high-value care. The weight of evidence supports the first-line use of budesonide for induction and, when appropriate, maintenance therapy. Because the technical review and guideline focused on treatments assessed in clinical trials, it did not address the full armamentarium of therapies currently used in practice. We would endorse clinical trials that more rigorously assess the effectiveness of lower-cost alternatives such as antidiarrheal agents (eg, loperamide) and cholestyramine monotherapy with accompanying cost-effective analyses. The role of combination therapies has yet to fully explored. Due to the absence of clinical trial data, this guideline did not address medical treatment of corticosteroid-refractory microscopic colitis. Very limited evidence from case series, however, suggests that immunosuppressants such as azathioprine and anti-tumor necrosis factor agents may benefit these patients. We encourage prospective clinical trials to further investigate these early findings.

Original languageEnglish (US)
Pages (from-to)242-246
Number of pages5
JournalGastroenterology
Volume150
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Fingerprint

Microscopic Colitis
Guidelines
Clinical Trials
Loperamide
Antidiarrheals
Cholestyramine Resin
Therapeutics
Budesonide
National Academies of Science, Engineering, and Medicine (U.S.) Health and Medicine Division
Azathioprine
Immunosuppressive Agents
Practice Guidelines
Cost-Benefit Analysis
Adrenal Cortex Hormones
Tumor Necrosis Factor-alpha
Weights and Measures
Costs and Cost Analysis

ASJC Scopus subject areas

  • Gastroenterology

Cite this

American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis. / Nguyen, Geoffrey C.; Smalley, Walter E.; Vege, Santhi Swaroop; Carrasco-Labra, Alonso.

In: Gastroenterology, Vol. 150, No. 1, 01.01.2016, p. 242-246.

Research output: Contribution to journalArticle

Nguyen, Geoffrey C. ; Smalley, Walter E. ; Vege, Santhi Swaroop ; Carrasco-Labra, Alonso. / American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis. In: Gastroenterology. 2016 ; Vol. 150, No. 1. pp. 242-246.
@article{417654170cee41019279bf9370b9713d,
title = "American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis",
abstract = "These actionable recommendations for the medical management of microscopic colitis were developed under the framework of the GRADE methodology and were consistent with the Institute of Medicine's Standards for Developing Trustworthy Clinical Practice Guidelines. This guideline is intended to reduce practice variation and promote high-value care. The weight of evidence supports the first-line use of budesonide for induction and, when appropriate, maintenance therapy. Because the technical review and guideline focused on treatments assessed in clinical trials, it did not address the full armamentarium of therapies currently used in practice. We would endorse clinical trials that more rigorously assess the effectiveness of lower-cost alternatives such as antidiarrheal agents (eg, loperamide) and cholestyramine monotherapy with accompanying cost-effective analyses. The role of combination therapies has yet to fully explored. Due to the absence of clinical trial data, this guideline did not address medical treatment of corticosteroid-refractory microscopic colitis. Very limited evidence from case series, however, suggests that immunosuppressants such as azathioprine and anti-tumor necrosis factor agents may benefit these patients. We encourage prospective clinical trials to further investigate these early findings.",
author = "Nguyen, {Geoffrey C.} and Smalley, {Walter E.} and Vege, {Santhi Swaroop} and Alonso Carrasco-Labra",
year = "2016",
month = "1",
day = "1",
doi = "10.1053/j.gastro.2015.11.008",
language = "English (US)",
volume = "150",
pages = "242--246",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis

AU - Nguyen, Geoffrey C.

AU - Smalley, Walter E.

AU - Vege, Santhi Swaroop

AU - Carrasco-Labra, Alonso

PY - 2016/1/1

Y1 - 2016/1/1

N2 - These actionable recommendations for the medical management of microscopic colitis were developed under the framework of the GRADE methodology and were consistent with the Institute of Medicine's Standards for Developing Trustworthy Clinical Practice Guidelines. This guideline is intended to reduce practice variation and promote high-value care. The weight of evidence supports the first-line use of budesonide for induction and, when appropriate, maintenance therapy. Because the technical review and guideline focused on treatments assessed in clinical trials, it did not address the full armamentarium of therapies currently used in practice. We would endorse clinical trials that more rigorously assess the effectiveness of lower-cost alternatives such as antidiarrheal agents (eg, loperamide) and cholestyramine monotherapy with accompanying cost-effective analyses. The role of combination therapies has yet to fully explored. Due to the absence of clinical trial data, this guideline did not address medical treatment of corticosteroid-refractory microscopic colitis. Very limited evidence from case series, however, suggests that immunosuppressants such as azathioprine and anti-tumor necrosis factor agents may benefit these patients. We encourage prospective clinical trials to further investigate these early findings.

AB - These actionable recommendations for the medical management of microscopic colitis were developed under the framework of the GRADE methodology and were consistent with the Institute of Medicine's Standards for Developing Trustworthy Clinical Practice Guidelines. This guideline is intended to reduce practice variation and promote high-value care. The weight of evidence supports the first-line use of budesonide for induction and, when appropriate, maintenance therapy. Because the technical review and guideline focused on treatments assessed in clinical trials, it did not address the full armamentarium of therapies currently used in practice. We would endorse clinical trials that more rigorously assess the effectiveness of lower-cost alternatives such as antidiarrheal agents (eg, loperamide) and cholestyramine monotherapy with accompanying cost-effective analyses. The role of combination therapies has yet to fully explored. Due to the absence of clinical trial data, this guideline did not address medical treatment of corticosteroid-refractory microscopic colitis. Very limited evidence from case series, however, suggests that immunosuppressants such as azathioprine and anti-tumor necrosis factor agents may benefit these patients. We encourage prospective clinical trials to further investigate these early findings.

UR - http://www.scopus.com/inward/record.url?scp=84952690354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952690354&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2015.11.008

DO - 10.1053/j.gastro.2015.11.008

M3 - Article

C2 - 26584605

AN - SCOPUS:84952690354

VL - 150

SP - 242

EP - 246

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -